Self-Adjuvanting Therapeutic Peptide-Based Vaccine Induce CD8⁺ Cytotoxic T Lymphocyte Responses in a Murine Human Papillomavirus Tumor Model

Title:Self-Adjuvanting Therapeutic Peptide-Based Vaccine Induce CD8⁺ Cytotoxic T Lymphocyte Responses in a Murine Human Papillomavirus Tumor Model

Volume: 12 Issue: 1

Author(s): Tzu-Yu Liu, Ashwini Kumar Giddam, Waleed M. Hussein, Zhongfan Jia, Nigel A.J. McMillan, Michael J. Monteiro, Istvan Toth and Mariusz Skwarczynski

Affiliation:

Keywords: Cytotoxic T lymphocyte (CTL) responses, human papillomavirus, peptide subunit vaccine, polyacrylate, selfadjuvanting, star-polymer, therapeutic anticancer vaccine.

Abstract: Vaccine candidates for the treatment of human papillomavirus (HPV)-associated cancers are aimed to activate T-cells and induce development of cytotoxic anti-tumor specific responses. Peptide epitopes derived from HPV-16 E7 oncogenic protein have been identified as promising antigens for vaccine development. However, peptide-based antigens alone elicit poor cytotoxic T lymphocyte (CTL) responses and need to be formulated with an adjuvant (immunostimulant) to achieve the desired immune responses. We have reported the ability of polyacrylate 4-arm star-polymer (S4) conjugated with HPV-16 E7_44-57 (8Q_min) epitope to reduce and eradicate TC-1 tumor in the mouse model. Herein, we have studied the mechanism of induction of immune responses by this polymer-peptide conjugate and found prompt uptake of conjugate by antigen presenting cells, stimulating stronger CD8⁺ rather than CD4⁺ or NK cell responses.

Cite this article as:

Liu Tzu-Yu, Giddam Kumar Ashwini, Hussein M. Waleed, Jia Zhongfan, McMillan A.J. Nigel, Monteiro J. Michael, Toth Istvan and Skwarczynski Mariusz, Self-Adjuvanting Therapeutic Peptide-Based Vaccine Induce CD8⁺ Cytotoxic T Lymphocyte Responses in a Murine Human Papillomavirus Tumor Model, Current Drug Delivery 2015; 12 (1) . https://dx.doi.org/10.2174/1567201811666141001155729